Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2023-02-14 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-02-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes amendments to a collaboration agreement between Vir Biotechnology and GlaxoSmithKline, detailing changes in their joint programs and rights. There are no financial statements or detailed financial performance data included. The document is an announcement of a material definitive agreement amendment, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or M&A filings. The document length is 5668 characters, which is sufficient to contain substantive information but it is clearly an 8-K current report announcing a material contract amendment rather than a full report or financial supplement.
2023-02-13 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-10 English
SCHEDULE 13G/A
Major Shareholding Notification
2023-02-09 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-09 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.